Cannabis Science To File Offering Memorandum for 25 Million USD in Expansion Capital
IRVINE, CA–(Marketwired – Apr 7, 2017) – Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce that it will file a 25 million USD offering memorandum to accommodate an aggressive expansion plan; the Company expects to file next week. The Company has been reviewing investment firms that have expressed interest in its business model and similar humanitarian interests. With this new growth plan the Company is now looking for a corporate office in NYC to facilitate its financing initiatives and its east coast expansion plans.
The Company has received a considerable increase in activity from its recent collaboration research agreement with Dana-Farber to research cannabis-based cancer treatments and multiple leadership speaking engagements at Harvard Medical School. The anticipated 25 Million in new funding will allow Cannabis Science to jump-start its aggressive Drug Development programs with its extensive cannabinoid formulation base targeting multiple critical ailments.
“As regulation changes swiftly in such an enormous expanding industry, it creates opportunities and it can create hurdles for those same opportunities. We must remain fluid and move as the regulations move. Our expansion program is being fueled by the growing market and demand. These investments are for individuals or corporations interested in participating in the CBIS property development projects and fund the future costs of FDA approval’s process and Drug and Developments costs for its related targets. This all adds additional strength to this ever changing and growing Cannabis industry and we are all very proud to be right in the middle of it all,” stated Mr. Raymond C. Dabney, President & CEO, Co-Founder, Cannabis Science Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer (CMO)
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
Cannabis Science, Inc.